Phase Ia single ascending dose controlled trial of AEM 28 in patients with elevated cholesterol levels.

Trial Profile

Phase Ia single ascending dose controlled trial of AEM 28 in patients with elevated cholesterol levels.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs AEM 28 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; First in man
  • Sponsors Capstone Therapeutics; LipimetiX
  • Most Recent Events

    • 02 Sep 2014 Status changed from `recruiting' to `completed', as reported by a Capstone Therapeutics media release.
    • 02 Sep 2014 Interim results published in a Capstone Therapeutics media release.
    • 09 Apr 2014 Dosing has been initiated, according to a media release from LipimetiX and Capstone Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top